Equity Profile

DXCM

DexCom, Inc.

Health CareHealth Care Equipment$34.5B

Jul29Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

DexCom, Inc. is a healthcare company that specializes in continuous glucose monitoring systems for people with diabetes....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and reflects the company's ability to generate profit for its shareholders.

0.67

Revenue

Revenue growth is essential for assessing the company's market performance and demand for its products.

1.3B

Wall Street expectations, options signals, track record, and call prep available with Pro.

DXCM Q2-2026 Earnings Preview

Context

Company Snapshot

DexCom, Inc. is a healthcare company that specializes in continuous glucose monitoring systems for people with diabetes. With a market cap of $34 billion, it plays a crucial role in improving diabetes management through innovative technology in the health care equipment sector.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+0.22%

Avg Stock Reaction

-0.38%

Last Quarter Recap

In Q1-2026, DexCom reported an EPS of $0.56, surpassing expectations by 19.66%. The stock reacted positively, gaining 3.46% the following day.

Management Promises & Guidance

Continued focus on expanding product offerings.
Commitment to improving customer service and support.
Plans to enhance technology for better glucose monitoring.

Expectations

Wall Street Expectations

Analysts expect DexCom to report strong earnings driven by increased demand for its glucose monitoring systems. The consensus EPS is set at $0.67, indicating confidence in the company's growth.

Bull Case

If DexCom exceeds EPS expectations and shows robust revenue growth, it could signal strong market demand and innovation, leading to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet earnings expectations or provides weak guidance, it could raise concerns about market competition and product adoption, negatively impacting the stock.

Key Metrics to Watch

EPS

0.67

Earnings per share is a key indicator of profitability and reflects the company's ability to generate profit for its shareholders.

Revenue

1.3B

Revenue growth is essential for assessing the company's market performance and demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will DexCom's EPS exceed the consensus estimate of $0.67?

A beat on EPS could indicate strong operational performance and boost investor confidence.

What guidance will management provide for future revenue growth?

Future revenue guidance will be crucial in assessing the company's growth trajectory and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate DexCom's ability to innovate and capture market share, leading to stronger-than-expected earnings.

Supporting Evidence

Recent product launches have received positive feedback, suggesting higher adoption rates.

The company's historical performance shows a pattern of beating EPS estimates.

Options pricing indicates heightened volatility, which may reflect investor optimism not captured in consensus estimates.

Key Risk

If revenue growth falls below $1.3 billion, it could challenge the optimistic earnings outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on DexCom's ability to meet or exceed earnings expectations while providing positive guidance.

Bull Confirmed If

An EPS of $0.70 or higher would confirm the bull case and indicate strong demand for DexCom's products.

Bear Confirmed If

An EPS below $0.62 would support the bear case, raising concerns about market competitiveness.

Pre-Earnings Positioning

Options Market

Implied Move

±14.1%

Historical Avg

±2.1%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±14.1% while DXCM has averaged ±2.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

46.5%

Calls (390K)P/C Ratio: 0.28Puts (105K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If DexCom beats expectations, history suggests a potential stock increase of around 2.13%, confirming strong market demand.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further commentary.

Miss

Should the company miss expectations, the average reaction has been a decline of about 0.65%, indicating market disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their market reception.
2Management's commentary on competitive landscape and market share.
3Insights into customer acquisition and retention strategies.
4Guidance on revenue expectations for the next quarter.
5Details on operational efficiencies and cost management.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

DexCom, Inc. is a healthcare company that specializes in continuous glucose monitoring systems for people with diabetes....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and reflects the company's ability to generate profit for its shareholders.

0.67

Revenue

Revenue growth is essential for assessing the company's market performance and demand for its products.

1.3B

Wall Street expectations, options signals, track record, and call prep available with Pro.

DXCM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+0.22%

Avg Stock Reaction

-0.38%

Last Quarter Recap

In Q1-2026, DexCom reported an EPS of $0.56, surpassing expectations by 19.66%. The stock reacted positively, gaining 3.46% the following day.

Management Promises & Guidance

Continued focus on expanding product offerings.
Commitment to improving customer service and support.
Plans to enhance technology for better glucose monitoring.

Expectations

Wall Street Expectations

Analysts expect DexCom to report strong earnings driven by increased demand for its glucose monitoring systems. The consensus EPS is set at $0.67, indicating confidence in the company's growth.

Bull Case

If DexCom exceeds EPS expectations and shows robust revenue growth, it could signal strong market demand and innovation, leading to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet earnings expectations or provides weak guidance, it could raise concerns about market competition and product adoption, negatively impacting the stock.

Key Metrics to Watch

EPS

0.67

Earnings per share is a key indicator of profitability and reflects the company's ability to generate profit for its shareholders.

Revenue

1.3B

Revenue growth is essential for assessing the company's market performance and demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will DexCom's EPS exceed the consensus estimate of $0.67?

A beat on EPS could indicate strong operational performance and boost investor confidence.

What guidance will management provide for future revenue growth?

Future revenue guidance will be crucial in assessing the company's growth trajectory and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate DexCom's ability to innovate and capture market share, leading to stronger-than-expected earnings.

Supporting Evidence

Recent product launches have received positive feedback, suggesting higher adoption rates.

The company's historical performance shows a pattern of beating EPS estimates.

Options pricing indicates heightened volatility, which may reflect investor optimism not captured in consensus estimates.

Key Risk

If revenue growth falls below $1.3 billion, it could challenge the optimistic earnings outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on DexCom's ability to meet or exceed earnings expectations while providing positive guidance.

Bull Confirmed If

An EPS of $0.70 or higher would confirm the bull case and indicate strong demand for DexCom's products.

Bear Confirmed If

An EPS below $0.62 would support the bear case, raising concerns about market competitiveness.

Pre-Earnings Positioning

Options Market

Implied Move

±14.1%

Historical Avg

±2.1%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±14.1% while DXCM has averaged ±2.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

46.5%

Calls (390K)P/C Ratio: 0.28Puts (105K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If DexCom beats expectations, history suggests a potential stock increase of around 2.13%, confirming strong market demand.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further commentary.

Miss

Should the company miss expectations, the average reaction has been a decline of about 0.65%, indicating market disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their market reception.
2Management's commentary on competitive landscape and market share.
3Insights into customer acquisition and retention strategies.
4Guidance on revenue expectations for the next quarter.
5Details on operational efficiencies and cost management.